Editas Medicine Inc (EDIT)
4.94
-0.14
(-2.76%)
USD |
NASDAQ |
Jun 26, 09:58
Editas Medicine SG&A Expense (Annual): 69.65M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 69.65M |
| December 31, 2022 | 70.70M |
| December 31, 2021 | 76.18M |
| December 31, 2020 | 67.58M |
| December 31, 2019 | 64.56M |
| Date | Value |
|---|---|
| December 31, 2018 | 55.01M |
| December 31, 2017 | 50.50M |
| December 31, 2016 | 46.26M |
| December 31, 2015 | 18.10M |
| December 31, 2014 | 7.65M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
64.56M
Minimum
2019
76.18M
Maximum
2021
69.73M
Average
69.65M
Median
2023
SG&A Expense (Annual) Benchmarks
| Vertex Pharmaceuticals Inc | 1.137B |
| Bristol-Myers Squibb Co | 7.772B |
| Regeneron Pharmaceuticals Inc | 2.631B |
| Cabaletta Bio Inc | 19.24M |
| Oragenics Inc | 5.452M |